MedTrace Logo

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

NCT05279300 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2025-08-11

No results posted yet for this study

Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.

Conditions

  • Advanced Solid Tumor
  • Advanced Lymphoma

Interventions

DRUG

CS5001

The dose and dosing schedule is decided by the Safety Monitoring Committee.

BIOLOGICAL

Rituximab

IV infusion

DRUG

Gemcitabine

IV infusion

DRUG

Oxaliplatin

IV infusion

DRUG

Lenalidomide

PO

DRUG

Cyclophosphamide

IV infusion

DRUG

Doxorubicin

IV infusion

DRUG

Vincristine

IV infusion

DRUG

Prednisone

PO

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279300 on ClinicalTrials.gov